FANIN, RENATO
 Distribuzione geografica
Continente #
NA - Nord America 3.679
AS - Asia 942
EU - Europa 812
SA - Sud America 10
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.453
Nazione #
US - Stati Uniti d'America 3.670
SE - Svezia 423
SG - Singapore 407
HK - Hong Kong 290
CN - Cina 187
RU - Federazione Russa 113
BG - Bulgaria 83
IE - Irlanda 81
IT - Italia 41
KR - Corea 27
DE - Germania 22
BE - Belgio 15
FI - Finlandia 10
IN - India 10
TR - Turchia 10
CA - Canada 9
SN - Senegal 8
UA - Ucraina 7
CH - Svizzera 6
BR - Brasile 5
AT - Austria 3
GB - Regno Unito 3
TW - Taiwan 3
CL - Cile 2
CZ - Repubblica Ceca 2
JP - Giappone 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
ES - Italia 1
GE - Georgia 1
ID - Indonesia 1
IL - Israele 1
IR - Iran 1
PH - Filippine 1
PK - Pakistan 1
PL - Polonia 1
RO - Romania 1
TN - Tunisia 1
Totale 5.453
Città #
Fairfield 615
Singapore 368
Ashburn 332
Hong Kong 290
Woodbridge 277
Chandler 257
Wilmington 241
Houston 236
Seattle 236
Cambridge 207
Princeton 166
Boardman 153
Ann Arbor 137
Beijing 87
Santa Clara 86
Jacksonville 85
Sofia 83
Dublin 81
Columbus 77
Moscow 50
San Diego 44
Seoul 27
Brussels 15
Trieste 14
Norwalk 13
Washington 10
Bremen 9
Dakar 8
Helsinki 8
Andover 7
Monmouth Junction 7
Bern 6
Fremont 6
Nanjing 6
Pune 6
Toronto 6
Kocaeli 5
Los Angeles 5
Shanghai 5
Kunming 4
Tianjin 4
Ankara 3
Augusta 3
Casier 3
Dallas 3
Hebei 3
Hefei 3
Mumbai 3
Redwood City 3
Shenyang 3
Vienna 3
Brno 2
Fuzhou 2
Guangzhou 2
Haikou 2
Jinan 2
Lappeenranta 2
Leawood 2
Lima 2
Milan 2
Naples 2
Padova 2
Redmond 2
San Jose 2
San Mateo 2
São Paulo 2
Taiyuan 2
Tappahannock 2
Wenzhou 2
Albuquerque 1
Belo Horizonte 1
Binangonan 1
Buffalo 1
Cangzhou 1
Castro Valley 1
Changchun 1
Changsha 1
Chongqing 1
Dearborn 1
Galati 1
Guaratingueta 1
Haifa 1
Hanover 1
Islamabad 1
Istanbul 1
Itabashi-ku 1
Izmir 1
Jakarta 1
Lanzhou 1
Lestizza 1
London 1
Munich 1
Nanchang 1
Nicosia 1
Ningbo 1
North Charleston 1
Nottingham 1
Palo Alto 1
Piemonte 1
Polska 1
Totale 4.376
Nome #
Low-dose rituximab in adult patients with primary immune thrombocytopenia 125
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 115
Rituximab for the treatment of type II mixed cryoglobulinemia 113
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 107
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 99
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 99
Rituximab in a case of cold agglutinin disease 98
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice 98
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 97
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 96
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion 94
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 94
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response 93
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 93
Bendamustine salvage therapy for T cell neoplasms 92
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 91
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 88
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 87
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 87
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma 87
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 86
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab 85
Management of immune thrombocytopenia in elderly patients 85
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 82
Treatment of refractory chronic GVHD with rituximab: a GITMO study 81
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 81
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 80
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment 79
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters 78
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 78
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 78
Meningeal and cerebral involvement in multiple myeloma patients 77
Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease 75
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 75
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 73
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 71
Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas 71
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 71
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 69
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 68
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 67
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma 67
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients 67
CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies? 67
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia 66
The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center 66
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma 65
The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease 63
Risk of C virus infection in Waldenstrom’s syndromes and monoclonal gammopathies 61
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 61
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: Results of a retrospective, observational GIMEMA study 61
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 61
Hepatitis C virus and lymphoproliferative disorders 59
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 59
Computed tomography, magnetic resonance and gallium 67 scintigraphy for the imaging of residual lymphoma 58
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults 58
Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation 57
Prevalence of Hepatitis C Virus infection in patients with lymphoproliferative disorder 55
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas 54
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 54
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 54
The role of Rituximab in the therapy of mixed cryoglobulinemia 53
Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance 53
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome 52
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas 51
High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome 51
Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine 47
Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome 47
High-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's lymphoma: a single center experience 47
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 46
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 44
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers 43
Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients 43
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies 42
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome 42
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation 42
Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording 39
Myasthenia gravis after allogeneic bone marrow transplantation: a case report 35
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study 34
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab 33
Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha 32
The F-MACHOP regimen in the treatment of aggressive non-Hodgkin’s lymphomas: a single centre experience in 72 patients 31
Myasthenia gravis after allogeneic bone marrow transplantation. A case report and a review of the literature 27
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 27
Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma 26
Totale 5.763
Categoria #
all - tutte 25.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.993


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020833 0 0 0 0 0 0 248 195 200 86 51 53
2020/20211.093 57 136 113 103 82 127 22 89 15 102 66 181
2021/2022937 17 106 2 131 4 23 49 32 113 73 38 349
2022/2023971 117 127 102 60 101 191 1 104 114 17 32 5
2023/2024689 28 29 69 15 33 94 122 181 30 10 44 34
2024/2025933 3 242 273 98 111 134 72 0 0 0 0 0
Totale 5.763